Raymond James Financial Inc. acquired a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 70,802 shares of the company's stock, valued at approximately $43,543,000. Raymond James Financial Inc. owned approximately 0.12% of argenx at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARGX. Whipplewood Advisors LLC acquired a new stake in argenx during the fourth quarter worth approximately $37,000. Global Retirement Partners LLC raised its holdings in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in argenx during the fourth quarter worth approximately $66,000. Finally, Nkcfo LLC acquired a new stake in argenx during the fourth quarter worth approximately $68,000. Institutional investors and hedge funds own 60.32% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on ARGX shares. Oppenheimer raised their target price on shares of argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. HC Wainwright raised their target price on shares of argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Citigroup restated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Guggenheim raised their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Wolfe Research upgraded shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 target price on the stock in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $687.00.
View Our Latest Stock Report on ARGX
argenx Stock Performance
Shares of NASDAQ ARGX opened at $580.43 on Wednesday. The firm has a market capitalization of $35.27 billion, a P/E ratio of -659.58 and a beta of 0.59. argenx SE has a one year low of $349.86 and a one year high of $678.21. The company's fifty day moving average is $640.47 and its two-hundred day moving average is $594.85.
argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, sell-side analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.
argenx Company Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Recommended Stories
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
